GH Research (GHRS) vs Pacira BioSciences (PCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pacira BioSciences (PCRX) has outperformed GH Research (GHRS) over the past year, gaining 55.4% versus a gain of 55.3%. Over five years, GHRS leads with a +20.3% price change compared with -31.6% for PCRX. GH Research is the larger company by market cap ($1.45 billion vs $1.45 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GHRS | PCRX |
|---|---|---|
| Share price | $21.16 | $36.32 |
| Market cap | $1.45B | $1.45B |
| 1-day change | +3.45% | -0.21% |
| YTD return | +61.02% | +40.61% |
| 1-year return | +55.28% | +55.45% |
| 5-year return | +20.29% | -31.60% |
| P/E ratio (TTM) | — | 103.76 |
| Forward P/E | — | 10.50 |
| EPS (TTM) | $-0.99 | $0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $726.41M |
| Revenue growth (YoY) | — | +3.63% |
| Net income (latest FY) | — | $7.03M |
| Gross margin | — | 79.39% |
| Operating margin | — | 2.64% |
| Net margin | — | 0.97% |
| 52-week high | $31.44 | $36.46 |
| 52-week low | $12.04 | $18.80 |
| Distance from 52-week high | -32.71% | -0.40% |
| Analyst consensus | none | buy |
| Avg. price target upside | +102.74% | -17.09% |
| Average volume | 294.29K | 1.03M |
| Shares outstanding | 68.64M | 39.91M |
| Employees | 73 | 825 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GH Research
GHRS stock →GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
GHRS vs PCRX FAQ
Which is bigger, GH Research or Pacira BioSciences?
GH Research (GHRS) is larger, with a market capitalization of $1.45B compared with $1.45B for Pacira BioSciences (PCRX).
Which stock has performed better over the past year, GHRS or PCRX?
PCRX returned +55.45% over the past 12 months, compared with +55.28% for GHRS (price return, excluding dividends). Past performance does not predict future results.
Are GH Research and Pacira BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.